P. Žák, M. Lucijanić
Welcome in the name of Gemfin
A. Álvarez-Larrán
Challenges in path. diagnosis of MPNs in 2025
H.M. Kvasnicka
Triple negative MPNs – when driver mutations can’t guide you
T. Sacha
Rare chronic myeloid neoplasms
A. Reiter
Individual risk scores and machine learning
G. Abu-Zeinah
BREAK
M. Sobas, A. Hatalová
Anticoagulation
M. Griesshammer
Rethinking risk-based treatment strategies in polycythemia vera
T. Barbui
Expectation from cytoreductive therapy in PV and ET
J.-J. Kiladjian
LUNCH BREAK
The right dose
H. Gisslinger
How to treat elderly/frail patients
H. Al-Ali
What more can be achieved with combination therapy?
H. Hasselbalch
BREAK
J. Schwarz, I. Ursuleac
Do we need a specific approach based on the mutational status in ET?
A. Álvarez-Larrán
Progress in early clinical research in MPN
J. O’Sullivan
Are we ready for mutation-guided therapy?
J. Scandura